Sarepta Therapeutics' shares plunged nearly 30% on Tuesday as the failure of two of its approved drugs in a key trial and weak forecast for its top selling gene therapy raised concerns about the ...
Parent Project Muscular Dystrophy (PPMD), the largest U.S. non-profit leading Duchenne and Becker muscular dystrophy care, research, and advocacy efforts, and MyoGene Bio (MyoGene) are excited to ...
Sarepta Therapeutics shares plunged 37% after two Duchenne muscular dystrophy drugs failed a key trial, raising regulatory ...
Sarepta Therapeutics stock was plummeting Tuesday after the biotechnology company disclosed disappointing trial data for two ...
Investor's Business Daily on MSN
Sarepta Crashes After Two Muscular Dystrophy Drugs Fail Confirmatory Tests
Sarepta stock crashed late Monday after the biotech company said two of its muscular dystrophy drugs failed their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback